ES2440390B1 - Composiciones para el tratamiento del sobrepeso y de la obesidad - Google Patents

Composiciones para el tratamiento del sobrepeso y de la obesidad Download PDF

Info

Publication number
ES2440390B1
ES2440390B1 ES201231198A ES201231198A ES2440390B1 ES 2440390 B1 ES2440390 B1 ES 2440390B1 ES 201231198 A ES201231198 A ES 201231198A ES 201231198 A ES201231198 A ES 201231198A ES 2440390 B1 ES2440390 B1 ES 2440390B1
Authority
ES
Spain
Prior art keywords
composition
overweight
obesity
treatment
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201231198A
Other languages
English (en)
Other versions
ES2440390A1 (es
Inventor
Josep Escaich Ferrer
Mª Luisa BONET PIÑA
Daniel MARTÍNEZ PUIG
Nuria GRANADOS BORBOLLA
Bàrbara REYNÉS MIRALLES
Carles Chetrit Russi
Andreu Palou Oliver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioiberica SA
Original Assignee
Bioiberica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioiberica SA filed Critical Bioiberica SA
Priority to ES201231198A priority Critical patent/ES2440390B1/es
Priority to ES13739437.5T priority patent/ES2673099T3/es
Priority to US14/416,164 priority patent/US20150182597A1/en
Priority to PCT/EP2013/065384 priority patent/WO2014016233A1/en
Priority to EP13739437.5A priority patent/EP2884956B1/en
Priority to CA2879645A priority patent/CA2879645C/en
Publication of ES2440390A1 publication Critical patent/ES2440390A1/es
Application granted granted Critical
Publication of ES2440390B1 publication Critical patent/ES2440390B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invención se refiere a una composición que comprende ácido hialurónico y sulfato de dermatano para su uso en el tratamiento o prevención de al menos una de las enfermedades que conforman el síndrome metabólico en un mamífero, seleccionada del grupo formado por sobrepeso, obesidad, resistencia a la insulina, diabetes tipo 2, hígado graso o dislipidemia. Además la composición puede contener hidrolizado de colágeno. La composición está en forma de composición farmacéutica.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10

Claims (1)

  1. imagen1
ES201231198A 2012-07-25 2012-07-25 Composiciones para el tratamiento del sobrepeso y de la obesidad Active ES2440390B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES201231198A ES2440390B1 (es) 2012-07-25 2012-07-25 Composiciones para el tratamiento del sobrepeso y de la obesidad
ES13739437.5T ES2673099T3 (es) 2012-07-25 2013-07-22 Composiciones que comprenden ácido hialurónico y sulfato de dermatano para el tratamiento del sobrepeso y de la obesidad
US14/416,164 US20150182597A1 (en) 2012-07-25 2013-07-22 Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity
PCT/EP2013/065384 WO2014016233A1 (en) 2012-07-25 2013-07-22 Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity
EP13739437.5A EP2884956B1 (en) 2012-07-25 2013-07-22 Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity
CA2879645A CA2879645C (en) 2012-07-25 2013-07-22 Compositions comprising hyaluronic acid and dermatan sulphate for the treatment of being overweight and obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231198A ES2440390B1 (es) 2012-07-25 2012-07-25 Composiciones para el tratamiento del sobrepeso y de la obesidad

Publications (2)

Publication Number Publication Date
ES2440390A1 ES2440390A1 (es) 2014-01-28
ES2440390B1 true ES2440390B1 (es) 2014-11-13

Family

ID=48808358

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201231198A Active ES2440390B1 (es) 2012-07-25 2012-07-25 Composiciones para el tratamiento del sobrepeso y de la obesidad
ES13739437.5T Active ES2673099T3 (es) 2012-07-25 2013-07-22 Composiciones que comprenden ácido hialurónico y sulfato de dermatano para el tratamiento del sobrepeso y de la obesidad

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13739437.5T Active ES2673099T3 (es) 2012-07-25 2013-07-22 Composiciones que comprenden ácido hialurónico y sulfato de dermatano para el tratamiento del sobrepeso y de la obesidad

Country Status (5)

Country Link
US (1) US20150182597A1 (es)
EP (1) EP2884956B1 (es)
CA (1) CA2879645C (es)
ES (2) ES2440390B1 (es)
WO (1) WO2014016233A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2610014C1 (ru) * 2016-03-23 2017-02-07 Наталья Павловна Михайлова Способ оздоровления
CN109924485A (zh) * 2019-03-29 2019-06-25 华熙生物科技股份有限公司 一种含透明质酸的减肥保健食品及其制备方法
FR3105729B1 (fr) * 2019-12-31 2023-07-21 Mrs Biotech Composition pour la gestion du poids d’un sujet
WO2021203081A1 (en) * 2020-04-03 2021-10-07 Dupont Nutrition Biosciences Aps Composition comprising eubacterium eligens dsm 33458, intestinimonas massiliensis dsm 33460, prevotella copri dsm 33457 and/or akkermansia dsm 33459

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780414A (en) 1985-01-18 1988-10-25 Bio-Technology General Corp. Method of producing high molecular weight sodium hyallronate by fermentation of streptococcus
IT1189085B (it) 1986-03-25 1988-01-28 Mediolanum Farmaceutici Srl Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono
JP2005046133A (ja) * 2003-10-20 2005-02-24 Medicaraise Corp ヒアルロン酸とデルマタン硫酸を含有する健康食品
ES2281265B1 (es) * 2005-11-24 2008-08-16 Bioiberica, S.A. Composiciones para el tratamiento de la artrosis.
US7763594B2 (en) * 2005-11-30 2010-07-27 Bioiberica, S.A. Compositions for the treatment of osteoarthritis and to nourish the synovial fluid
JP2008150326A (ja) * 2006-12-18 2008-07-03 Globe Company Inc ドリンク剤
JP2010059084A (ja) * 2008-09-03 2010-03-18 Q P Corp 機能性食品及び医薬
ES2579340T3 (es) * 2010-04-12 2016-08-10 Esm Holdings, Llc Una composición que comprende membrana de cáscara de huevo en polvo para su uso en el tratamiento de mamíferos prediabéticos

Also Published As

Publication number Publication date
CA2879645C (en) 2020-07-28
US20150182597A1 (en) 2015-07-02
ES2440390A1 (es) 2014-01-28
CA2879645A1 (en) 2014-01-30
WO2014016233A1 (en) 2014-01-30
EP2884956B1 (en) 2018-03-21
EP2884956A1 (en) 2015-06-24
ES2673099T3 (es) 2018-06-19

Similar Documents

Publication Publication Date Title
CO2021015060A2 (es) Agonistas de glp-1r y usos de los mismos
CL2013003025A1 (es) Compuestos derivados de pirimidinas de diaminocarboxamida y diaminocarbonitrilo, como inhibidores de quinasa jnk; composicion farmaceutica; metodo de inhibicion in vitro; y su uso en el tratamiento o prevencion de trastornos fibroticos del higado, diabetes o sindrome metabolico conduciendo a trastornos fibroticos del higado.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
CU20140151A7 (es) Composición farmacéutica útil en la prevención de un evento cardiovascular mayor
NZ611606A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
BR112012018585A2 (pt) conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
DK2838549T3 (da) Farmaceutisk præparat til forebyggelse eller behandling af ikke-alkoholisk fedtleversygdom
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
ES2440390B1 (es) Composiciones para el tratamiento del sobrepeso y de la obesidad
DOP2013000125A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
BR112015018259A2 (pt) Redução de resposta pró-inflamatória
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
BR112012018703A2 (pt) compostos e seus efeitos sobre o comportamento alimentar
ES2508165T3 (es) Lactoferrina y sustancia blanca
ES2452034T5 (es) Composición para el cuidado de prótesis dental

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2440390

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141113